Search

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more

Chairs and Members

Chair and affiliation:
Willem E.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

The European Union must deliver funding for research of blood disorders

At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.

Read more

Publications

The publications of the ESLHO networks can be found on the following pages:

EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.

Read more

Report on first EHA-SWG Scientific Meeting

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.

Read more

Chairs and Members

The EHA SWG commenced in 2020, but initial work was delayed due to the COVID-19 pandemic. We therefore started in 2021, in preparation for a (successful) SWG meeting in 2022.

Read more

Publications

For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.

Read more